MANNKIND CORP (MNKD)

Nasdaq · SEC-listed source profile
Back to Stock Research

Listing facts

SEC issuer name
MANNKIND CORP
Ticker
MNKD
Exchange
Nasdaq
Instrument family
Not yet reviewed
SEC issuer CIK
0000899460
Listing source refreshed
2026-09-13

SEC listing source

Company Research Map

These reviewed encyclopedia concepts are supported by public-company evidence for this business. Operating-model groups show how the reported concepts fit together without implying that every metric in the broader model is reported by this issuer.

Biopharma Development and Commercialization

3 reviewed concepts

Connect clinical-trial evidence, FDA application and expedited pathways, collaboration economics, gross-to-net commercialization, and loss-of-exclusivity risk to understand drug-development businesses.

How these metrics connect

These bridges come from the reviewed operating model. Linked concepts have public-company evidence for this issuer; broader bridge coverage remains explicit when the model contains additional concepts.

FDA pathway and review milestones
3 of 6 reviewed concepts

NDA and BLA submissions begin formal marketing review for drugs and biologics, PDUFA dates frame target action timing, and accelerated approval, Breakthrough Therapy, and Orphan Drug designations describe distinct regulatory pathways or incentives rather than approval outcomes.